Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab and Nuwiq in Hemophilia A PUPs and ITI
NCT04030052Phase 3Withdrawn
- Sponsor
- Emory University
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Emory University. Planned start Feb 2022; status: withdrawn.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04030052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030052.